Company intelligence / Profile preview

Curium

Ownership: Private
Development stage: Commercial

Overview

Curium is the world’s leading radiopharmaceutical company specializing in both diagnostic and therapeutic nuclear medicine. It serves over 14 million patients annually across more than 60 countries. Its portfolio covers SPECT, PET tracers, cold kits, hot products, and therapeutic radioligands. The company has a strong oncology focus—especially neuroendocrine tumors and prostate cancer—and recently submitted an NDA to the FDA for its formulation of lutetium Lu177 dotatate injection targeting SSTR-positive GEP-NETs.

Therapeutic areas: Oncology
Modalities: Radiopharmaceuticals (including SPECT and PET tracers)Therapeutic radioligands (e.g., lutetium-based therapies)Diagnostic agents for nuclear imaging
Industry: Biotech

Drug pipeline

25 assets

technetium-99m-methylene diphosphonate

Approved

24 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed in public sources; collaborates widely with hospitals/healthcare providers globally.

Beyond the preview

Go deeper on Curium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curium.

Explore the full profile